Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Survival with liver transplant in primary biliary cirrhosis is high

The latest Clinical Transplantation shows excellent survival rates with 15 years follow-up after liver transplantation in primary biliary cirrhosis, and that recipient's age, and tacrolimus immunosuppression are risk factors recurrence.

News image

fiogf49gjkf04

Orthotopic liver transplantation is the only effective curative therapy for end-stage primary biliary cirrhosis.

Survival after orthotopic liver transplantation is excellent.

However, recent data have shown a recurrence rate of primary biliary cirrhosis of up to 32% after transplantation.

Dr Dietmar Jacoba and colleagues from Germany investigated the course after disease recurrence.

The researchers particularly assessed liver function and survival with long-term follow-up.

The team performed 1553 liver transplantations in 1415 patients at the Charité, Virchow Clinic, between 1989 and 2003.

Protocol liver biopsies were taken after 1, 3, 5, 7, 10 and 13 years.

The team reported that 7% of patients suffered from histologically proven primary biliary cirrhosis.

Patient survival after 15 years was 82%
Clinical Transplantation

Primary immunosuppression consisted of cyclosporine or tacrolimus.

Immediately after orthotopic liver transplantation, all patients received ursodeoxycholic acid.

The research team withdrew corticosteroids 3 to 6 months after orthotopic liver transplantation.

The team noted that the median age of the 85 women and 15 men was 55 years.

The median follow-up after liver transplantation was 118 months, and 30 months after recurrence 30 months.

The researchers found that actuarial patient survival after 5, 10 and 15 years was 87%, 84% and 82% respectively.

The team reported that 10% of patients died after a median survival time of 32 months.

Of the patients that died, 2 developed organ dysfunction owing to recurrence of primary biliary cirrhosis.

Histological recurrence was found in 14% of patients after a median time of 61 months.

The team observed that patients with tacrolimus immunosuppression developed primary biliary cirrhosis recurrence more often, and also earlier.

The research team identified 57 patients that developed an acute rejection, and 2 patients with a chronic rejection episode.

Liver function did not alter within the first 5 years after histologically proven primary biliary cirrhosis recurrence.

Dr Jacoba's team concluded, “Multivariate analysis of the investigated patients showed that the recipient's age and tacrolimus immunosuppression were significant risk factors for primary biliary cirrhosis recurrence.”

“Long-term follow-up of up to 15 years after liver transplantation, owing to primary biliary cirrhosis, in addition to maintenance of liver function, shows excellent organ and patient survival rates.”

“Although protocol liver biopsies revealed histological recurrence in 14% patients, only 2 patients developed graft dysfunction.”

“Tacrolimus-treated patients showed more frequently and also earlier histologically proven primary biliary cirrhosis recurrence.”

“However, in our population we could not observe an impact on graft dysfunction and patient's survival.”

Clin Transplant 2006:20(2):211
09 May 2006

Go to top of page Email this page Email this page to a colleague

 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us